Benitec Biopharma Reports $11.9 Million Net Loss for Quarter, Advances BB-301 Clinical Trial

Benitec Biopharma Inc. has reported its financial results for the three and nine months ended March 31, 2026, revealing a net loss of $11.9 million for the quarter, a decrease from a loss of $14.5 million in the same period last year. For the nine months, the company recorded a net loss of $32.7 million, compared to $29.1 million for the prior year. The company did not generate any revenue during these periods, consistent with its ongoing focus on research and development rather than commercial sales.

Total operating expenses for the three months ended March 31, 2026, were $13.6 million, down from $15.3 million in the same quarter of 2025. Research and development expenses slightly decreased to $6.3 million from $6.5 million year-over-year, while general and administrative expenses also fell to $7.3 million from $8.8 million. The reduction in general and administrative expenses was primarily attributed to a decrease in share-based compensation, which was offset by increases in salaries and wages.

In terms of operational developments, Benitec is advancing its lead product candidate, BB-301, for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The company has initiated a Phase 1b/2a clinical trial for BB-301, with the first study subject treated in November 2023. The trial aims to evaluate the safety and clinical activity of the treatment, which has received Orphan Drug Designation in both the U.S. and the EU. As of March 31, 2026, the company had cash and cash equivalents of approximately $184.8 million, bolstered by financing activities that generated $98.7 million in the nine months ended March 31, 2026.

Benitec's financial position reflects a significant increase in cash reserves compared to $97.7 million as of June 30, 2025, primarily due to successful capital raises through common stock issuances. The company has issued a total of 7.7 million shares of common stock during the nine months, generating gross proceeds of $104.5 million. The company anticipates that its cash reserves will be sufficient to fund operations for at least the next twelve months, although it acknowledges the need for additional financing to support ongoing development activities.

Looking ahead, Benitec Biopharma remains focused on advancing its clinical programs and exploring strategic partnerships to enhance its product development capabilities. The company is aware of the competitive landscape in the biotechnology sector and is committed to navigating the challenges associated with bringing its innovative therapies to market. The management emphasizes the importance of maintaining financial discipline while pursuing opportunities for growth and collaboration in the field of genetic medicine.